Boundless Bio, Inc. (BOLD)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
2.83 USD
-0.03
(-1.049%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.83 |
Hot Take ↕ | Aug. 22, 2026, 5:39 a.m. EDT
The immediate outlook remains neutral due to a lack of clear directional momentum, despite the stock trading near its 52-week highs relative to the recent past. While the price has rallied significantly from its 2025 lows, the underlying business fundamentals are severely compromised. The company is burning through cash rapidly, with negative free cash flow and operating cash flow, while posting substantial losses on both assets and equity. This financial distress is compounded by a catastrophic one-year price decline of nearly 68%, signaling that the market has lost faith in the current trajectory. Furthermore, there is no dividend income to offset these risks, making the investment purely speculative given the deteriorating operational metrics. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.586184 |
| AutoETS | 0.592517 |
| AutoARIMA | 0.592517 |
| AutoTheta | 0.618674 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 1.66 |
| Ljung-Box p | 0.009 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 10.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 64,376,792 |
| Forward P/E | -2.89 |
| Beta | 0.38 |
| Website | https://boundlessbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4869566 |
| Address1 | 10,955 Alexandria Way |
| Address2 | Suite 100 |
| All Time High | 15.24 |
| All Time Low | 0.961 |
| Ask | 3.63 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 122,930 |
| Average Daily Volume3 Month | 1,295,438 |
| Average Volume | 1,295,438 |
| Average Volume10Days | 122,930 |
| Beta | 0.383 |
| Bid | 2.06 |
| Bid Size | 2 |
| Book Value | 2.936 |
| City | San Diego |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.83 |
| Current Ratio | 9.481 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.86 |
| Day Low | 2.8 |
| Ebitda | -64,226,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.129 |
| Enterprise Value | -8,253,393 |
| Eps Current Year | -2.53 |
| Eps Forward | -0.98 |
| Eps Trailing Twelve Months | -2.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.5597 |
| Fifty Day Average Change | 0.2702999 |
| Fifty Day Average Change Percent | 0.10559828 |
| Fifty Two Week Change Percent | 148.69566 |
| Fifty Two Week High | 3.164 |
| Fifty Two Week High Change | -0.3340001 |
| Fifty Two Week High Change Percent | -0.10556261 |
| Fifty Two Week Low | 0.961 |
| Fifty Two Week Low Change | 1.869 |
| Fifty Two Week Low Change Percent | 1.944849 |
| Fifty Two Week Range | 0.961 - 3.164 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,711,632,600,000 |
| Float Shares | 16,084,280 |
| Forward Eps | -0.98 |
| Forward P E | -2.887755 |
| Free Cashflow | -30,552,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 28 |
| Fullday Change | -0.03 |
| Fullday Change Percent | -1.04895 |
| Fullday Price | 2.83 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11213 |
| Held Percent Institutions | 0.67264 |
| Implied Shares Outstanding | 22,747,985 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California. |
| Long Name | Boundless Bio, Inc. |
| Market | us_market |
| Market Cap | 64,376,792 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_637641859 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -64,012,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 65,741,676 |
| Number Of Analyst Opinions | 1 |
| Open | 2.82 |
| Operating Cashflow | -56,247,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 766 9912 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.83 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 2.86 |
| Price Eps Current Year | -1.118577 |
| Price Hint | 4 |
| Price To Book | 0.9638964 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.349 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03 |
| Regular Market Change Percent | -1.04895 |
| Regular Market Day High | 2.86 |
| Regular Market Day Low | 2.8 |
| Regular Market Day Range | 2.8 - 2.86 |
| Regular Market Open | 2.82 |
| Regular Market Previous Close | 2.86 |
| Regular Market Price | 2.83 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 75,542 |
| Return On Assets | -0.32773 |
| Return On Equity | -0.67857003 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 22,747,985 |
| Shares Percent Shares Out | 0.030299999 |
| Shares Short | 689,441 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 240,423 |
| Short Name | Boundless Bio, Inc. |
| Short Percent Of Float | 0.0502 |
| Short Ratio | 2.76 |
| Source Interval | 15 |
| State | CA |
| Symbol | BOLD |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 72,626,000 |
| Total Cash Per Share | 3.193 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.587575 |
| Two Hundred Day Average Change | 1.242425 |
| Two Hundred Day Average Change Percent | 0.78259295 |
| Type Disp | Equity |
| Volume | 75,542 |
| Website | https://boundlessbio.com |
| Zip | 92,121 |